Thermo Fisher Scientific Inc. $TMO Shares Sold by Metis Global Partners LLC

Metis Global Partners LLC cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 24.9% in the second quarter, HoldingsChannel reports. The firm owned 17,652 shares of the medical research company’s stock after selling 5,841 shares during the quarter. Metis Global Partners LLC’s holdings in Thermo Fisher Scientific were worth $7,157,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in TMO. Wedbush Securities Inc. increased its stake in shares of Thermo Fisher Scientific by 7.1% during the second quarter. Wedbush Securities Inc. now owns 4,066 shares of the medical research company’s stock worth $1,649,000 after buying an additional 270 shares during the period. Rovin Capital UT ADV lifted its holdings in Thermo Fisher Scientific by 14.0% during the 2nd quarter. Rovin Capital UT ADV now owns 820 shares of the medical research company’s stock worth $332,000 after buying an additional 101 shares during the last quarter. Harvest Portfolios Group Inc. boosted its position in shares of Thermo Fisher Scientific by 30.3% during the 2nd quarter. Harvest Portfolios Group Inc. now owns 129,916 shares of the medical research company’s stock worth $52,676,000 after acquiring an additional 30,176 shares in the last quarter. Nvwm LLC increased its holdings in shares of Thermo Fisher Scientific by 10.9% in the 2nd quarter. Nvwm LLC now owns 5,385 shares of the medical research company’s stock valued at $2,183,000 after acquiring an additional 529 shares during the last quarter. Finally, Bryn Mawr Trust Advisors LLC lifted its stake in Thermo Fisher Scientific by 1.9% during the second quarter. Bryn Mawr Trust Advisors LLC now owns 8,305 shares of the medical research company’s stock worth $3,367,000 after purchasing an additional 158 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $572.72 on Friday. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97. The stock has a market cap of $215.18 billion, a PE ratio of 33.09, a P/E/G ratio of 3.27 and a beta of 0.82. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. The stock has a fifty day moving average price of $518.58 and a 200 day moving average price of $462.39.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. The firm had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.Thermo Fisher Scientific’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.94%.

Thermo Fisher Scientific declared that its board has approved a share buyback program on Thursday, November 6th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 2.4% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on TMO shares. Cowen reissued a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. JPMorgan Chase & Co. upped their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research note on Thursday, October 9th. UBS Group boosted their target price on Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a report on Thursday, October 23rd. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. Finally, HSBC reiterated a “hold” rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Nineteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $601.65.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 7,250 shares of Thermo Fisher Scientific stock in a transaction on Monday, October 27th. The shares were sold at an average price of $566.10, for a total value of $4,104,225.00. Following the completion of the sale, the chief executive officer owned 113,762 shares in the company, valued at approximately $64,400,668.20. The trade was a 5.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 36,420 shares of company stock valued at $19,980,884. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.